Infinity Pharmaceuticals (INFI) Shares are Up 10%

Infinity Pharmaceuticals (INFI) : Traders are bullish on Infinity Pharmaceuticals (INFI) as it has outperformed the S&P 500 by a margin of 9.28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.33%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10% in the last 1 week, and is up 16.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Infinity Pharmaceuticals (NASDAQ:INFI): The stock opened at $1.59 on Friday but the bulls could not build on the opening and the stock topped out at $1.59 for the day. The stock traded down to $1.51 during the day, due to lack of any buying support eventually closed down at $1.54 with a loss of -3.75% for the day. The stock had closed at $1.60 on the previous day. The total traded volume was 779,590 shares.


The stock has recorded a 20-day Moving Average of 10.99% and the 50-Day Moving Average is 50.04%. Infinity Pharmaceuticals, Inc. has dropped 76.49% during the last 3-month period . Year-to-Date the stock performance stands at -80.38%.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *